BioMarin Pharmaceutical (BMRN)

Executive Summary

BioMarin Pharmaceutical is a global biotechnology leader focused on developing innovative therapies for rare genetic diseases, with a strong commercial portfolio including Vimizim, Naglazyme, Kuvan, and vosoritide (Voxzogo) for achondroplasia. The company continues to advance its pipeline, notably with valoctocogene roxaparvovec (Roctavian), a gene therapy for severe hemophilia A that is approved in Europe but faces regulatory hurdles in the US; a long-term follow-up study is ongoing. Additionally, early-stage programs like BMN 349 for Alpha-1 antitrypsin deficiency are progressing. BioMarin's deep expertise in biologics and rare diseases underpins its growth prospects, though near-term catalysts center on pipeline data updates and potential label expansions, particularly for vosoritide.

Upcoming Catalysts (preview)

• H2 2026Valoctocogene roxaparvovec long-term efficacy/safety data or FDA resubmission update60% success
• Q3 2026Vosoritide label expansion for younger children with achondroplasia (Phase 2 data readout)70% success
• Q3 2026BMN 349 Phase 1 data readout for Alpha-1 antitrypsin deficiency50% success